X

Trial Profile

CERTIC: Italian registry to evaluate long term efficacy of everolimus for prevention of transplant rejection

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 04 Nov 2015

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary)
Indications Heart transplant rejection; Renal transplant rejection
Focus Therapeutic Use
Acronyms CERTIC

Most Recent Events

16 Sep 2015 Results: Renal transplant recipients at 5 years, presented at the 17th Congress of the European Society for Organ Transplantation
15 May 2013 New trial record
27 Apr 2013 2-year results presented at the 33rd Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com